{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T18:40:04Z","timestamp":1759862404946,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clinthera.2025.06.009","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T17:57:24Z","timestamp":1759859844000},"page":"950-951","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Letter to the Editor Regarding \u201cTreatment Persistence Among Anti\u2013Tumor Necrosis Factor\u2013experienced Patients With Ulcerative Colitis Switching to a Biologic With a Different Mode of Action or Cycling to Another Anti\u2013Tumor Necrosis Factor Agent\u201d"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0248-4208","authenticated-orcid":false,"given":"Joaqu\u00edn","family":"Borr\u00e1s-Blasco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Valcuende-Rosique","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Cornejo-Uixeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.06.009_bib0001","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.clinthera.2024.12.002","article-title":"Treatment persistence among anti\u2013tumor necrosis factor\u2013experienced patients with ulcerative colitis switching to a biologic with a different mode of action or cycling to another anti\u2013tumor necrosis factor agent","volume":"47","author":"Zhdanava","year":"2025","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2025.06.009_bib0002","doi-asserted-by":"crossref","first-page":"T141","DOI":"10.1016\/j.farma.2023.07.020","article-title":"Persistence, current state of the art","volume":"48","author":"Rodriguez Goicoechea","year":"2024","journal-title":"Farm Hosp"},{"key":"10.1016\/j.clinthera.2025.06.009_bib0003","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/jdv.15600","article-title":"Expert consensus on the persistence of biological treatments in moderate-to-severe psoriasis","volume":"33","author":"de la Cueva Dobao","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clinthera.2025.06.009_bib0004","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jhqr.2023.10.005","article-title":"The value of persistence in the 5P Medicine model for chronic diseases","volume":"39","author":"Borras-Blasco","year":"2024","journal-title":"J Healthc Qual Res"},{"key":"10.1016\/j.clinthera.2025.06.009_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhqr.2025.101123","article-title":"Influence of adherence on persistence value inside Medicina 6P [in Spanish]","volume":"40","author":"Borr\u00e1s-Blasco","year":"2025","journal-title":"J Healthc Qual Res"},{"key":"10.1016\/j.clinthera.2025.06.009_bib0006","doi-asserted-by":"crossref","first-page":"mzae026","DOI":"10.1093\/intqhc\/mzae026","article-title":"Integration of persistence in the 5P-medicine approach for age-related chronic diseases","volume":"36","author":"Borr\u00e1s-Blasco","year":"2024","journal-title":"Int J Qual Health Care"},{"key":"10.1016\/j.clinthera.2025.06.009_bib0007","first-page":"296","article-title":"Evaluation of persistence, retention \u201crate\u201d and prescription pattern of original infliximab and infliximab CT-P13 in biologic-na\u00efve patients with ulcerative colitis","volume":"46","author":"Valcuende-Rosique","year":"2022","journal-title":"Farm Hosp"},{"key":"10.1016\/j.clinthera.2025.06.009_bib0008","article-title":"Persistence After Switching From Adalimumab Biosimilar MSB11022 to Adalimumab Biosimilar GP2017 in Patients With Chronic Inflammatory Rheumatic Diseases","author":"Borr\u00e1s-Blasco","year":"2024","journal-title":"J Pharm Technol"},{"key":"10.1016\/j.clinthera.2025.06.009_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.farma.2024.10.017","article-title":"Long-term persistence with secukinumab in patients with moderate-to-severe psoriasis","author":"Borr\u00e1s-Blasco","year":"2025","journal-title":"Farm Hosp"},{"key":"10.1016\/j.clinthera.2025.06.009_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.farma.2024.10.017","article-title":"Long-term persistence with secukinumab in patients with moderate-to-severe psoriasis","author":"Borr\u00e1s-Blasco","year":"2025","journal-title":"Farm Hosp"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825002152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825002152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T17:58:23Z","timestamp":1759859903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825002152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0149291825002152"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.06.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Letter to the Editor Regarding \u201cTreatment Persistence Among Anti\u2013Tumor Necrosis Factor\u2013experienced Patients With Ulcerative Colitis Switching to a Biologic With a Different Mode of Action or Cycling to Another Anti\u2013Tumor Necrosis Factor Agent\u201d","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.12.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}